Biologics Drug Discovery.
Eliminate variability & optimize your lead candidates.
Monoclonal antibodies are characterized by their vast diversity in both structure and activity. As such, researchers may evaluate hundreds of mAbs while identifying their best binders. But this selection process can take months as conventional techniques for biologics discovery do not include tools that can truly assess mAb biophysical diversity that directly affects specificity and affinity. With next generation protein sequencing (NGPS), mAb leads can be analyzed down to the amino acid level for targeted and controlled development in parallel.
Polyclonal antibodies are well used in drug discovery research because they recognize and bind many different epitopes of a single antigen; however, polyclonal mixtures are difficult to work with due to the lack of information of each antibody in the mixture. pAb sequencing allows direct access to high-affinity antibodies from the native immune response, deriving their amino acid sequences, which can be expressed as a set of mAbs that perform as well or better than the original polyclonal mixture. pAb sequencing is the most direct method for therapeutic antibody discovery.
Services for Biologics Drug Discovery.
We support the biologics drug discovery and validation pipeline with direct access to the amino acid sequence of the functional protein.. Contact Us to discover how we can help with your biologics drug discovery application.
Antibody Sequencing & Discovery Services.
de novo mAb Sequencing
Examine fusion products and derive the sequence of important candidates, or extract the CDR sequences to add to your framework or platform for future engineering.
Explore REmAb
Therapeutic mAb Discovery and Development
Exploit the therapeutic potential of circulating pAbs. Access a wide array of biologically relevant CDRs for antibody engineering, or extract exact sequences from the diverse antibody repertoire for recombinant expression.
Explore REpAb + Expression
Research Security
A biologic’s amino acid sequence is often integral to its IP. Thanks to Rapid Novor’s NGPS, scientists from the top 18 pharma have safeguarded their discoveries by directly accessing the protein sequence of their mAb drugs.
Explore MATCHmAb
Regulatory Approval and ADA
Anti-drug antibody assays are vital to establish clinical safety and efficacy of biologics. REpAb® polyclonal antibody sequencing can capture reliable control reagents that faithfully recapitulate the ADA response.
Explore REpAb
Binding Kinetics
Measure key antibody properties (ie. binding affinity, specificity, kinetics) to screen and identify lead candidates with optimal therapeutic potential.
Explore SPR
Epitope Mapping
Identify linear, conformational, and structural epitopes. Characterize antibody binding sites on target antigens for FDA and EMEA regulatory filings and IP protection.
Explore HDX-MS
Application Publications.
Therapeutic Antibody Discovery: From Target to Candidate
Written by: Genya Gorshtein, MSc Published: February 17, 2023 Contents Introduction Target Discovery and [...]
Antibody-Drug Conjugates as Anti-Cancer Therapeutics
Written by: Genya Gorshtein, MSc Published: September 14, 2022 Contents Introduction ADCs as Novel Anti-Cancer [...]
What are Polyclonal Antibodies?
Written by: Genya Gorshtein, MSc Published: August 18, 2022 Contents Introduction How are Polyclonal [...]
Structure and Function of Antibodies
Written by Genya Gorshtein, MSc August 10, 2022 Contents General Structure of Antibodies Fab and Fc [...]
“We’re focused on coupling cytokines with a highly engineered VHVL of an antibody. So by sequencing the antibodies with Rapid Novor we are able to pull out the CDR to graft them into our platform and test in vitro and in vivo.”
Pavel Khrimian – Co-founder and CBO, Deka Biosciences
Talk to Our Scientists.
We Have Sequenced 8000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 8000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics